Filing Flows › Industrials › Precipio (PRPO)
Precipio (PRPO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Precipio (PRPO) Q2 2026 earnings results →
Q2 2026 Revenue up 24% year over year to $7.0M · 3¢ of every $1 of revenue lost · operating margin -8.5%
Precipio made $7.0M in Q2 2026 (+24% Y/Y): Service revenue, net $6.1M, Product revenue $906K. Operating margin -8.5%, net loss $219K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.0M in Q2 2026, up 24% year over year and up 5% from the previous quarter. Service revenue, net was the largest line at 87% of revenue. Service revenue, net added $1.1M year over year (up 22%), 79% of the total change.
Gross margin was 44.7%, up 1.7 points from Q2 2025. Operating costs exceeded revenue by $599K, an operating margin of -8.5%. Operating expenses grew 15% against revenue growth of 24%. The quarter ended with a net loss of $219K, narrower than the previous quarter's $1.4M loss. Non-operating items added $380K, -174% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $660K (up 87% year over year). Non-cash charges added back $291K of depreciation and amortization and $767K of share-based compensation. Working capital and other items used $179K. Capital expenditures of $132K left free cash flow of $528K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $7.0M | +24% | -8.5% | −$219K | $660K |
| Q1 2026 | 10-Q | May 14, 2026 | $6.7M | +36% | -21.3% | −$1.4M | $64K |
| Q4 2025 | 10-K | Mar 30, 2026 | $6.7M | +23% | 8.1% | $526K | $366K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $6.8M | +30% | -0.9% | −$79K | $10K |
| Q2 2025 | 10-Q | Aug 13, 2025 | $5.7M | +27% | -14.6% | $74K | $353K |
| Q1 2025 | 10-Q | May 14, 2025 | $4.9M | +44% | -17.4% | −$884K | −$44K |
| Q4 2024 | 10-K | Mar 27, 2025 | $5.5M | +26% | -6.2% | −$365K | $565K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 40% of its revenue · Stated in 10-K (sentence) · source
About Precipio
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development. By integrating diagnostic services with product development, our service business doubles as a self-funded research and development (“R&D”) unit, enabling us to achieve rapid and cost-efficient innovation rather than being a major cost center for us.
In its own words, from its 10-K, filed Mar 30, 2026.
Precipio against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +24% against the peers' median +5%. Operating margin: -8.5% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PRPO Precipio | Q2 2026 | $7.0M | +24% | -8.5% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Precipio 10-Q on SEC EDGAR · CIK 1043961 · Laboratory Analytical Instruments
13F: who owns PRPO and who is buying
More on PRPO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results